Mavacamten Improves Health Status in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

EXPLORER-HCM data show improved symptom burden, physical function, and quality of life with mavacamten versus placebo.

In the industry-funded, randomized, controlled EXPLORER-HCM trial, mavacamten, a non–FDA-approved selective cardiac myosin inhibitor, improved peak oxygen consumption (VO₂) and New York Heart Association classification compared with placebo among individuals with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Given that a principal objective of treatment is to improve health status (symptoms, physical function, and quality of life), the trial investigators conducted a secondary analysis of the impact of mavacamten on scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ), a validated instrument for characterizing quality of life in patients with symptoms of heart failure.

The analysis included 180 EXPLORER-HCM participants…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)